Hagymási Krisztina, Bacsárdi Anna, Egresi Anna, Berta Evelin, Tulassay Zsolt, Lengyel Gabriella
Általános Orvostudományi Kar, II. Belgyógyászati Klinika, Semmelweis Egyetem Budapest, Szentkirályi u. 46., 1088.
Általános Orvostudományi Kar, Semmelweis Egyetem Budapest.
Orv Hetil. 2018 Sep;159(36):1465-1474. doi: 10.1556/650.2018.31178.
The community of microorganisms in the intestine, namely gut microbiome lives in symbiosis with the host, contributing to its homeostasis and influencing it simultaneously. It can be suspected that gut microbiome plays a central role in the pathophysiology of intestinal and extraintestinal diseases: determining their development, progress and complications. Recently, intestinal microbiome has become a highlighted field of interest and important topic in research, especially in hepatology. It is in the focus of relevant research as the liver is the organ which meets nutrients, bacterial components, toxins and metabolites at first, as a filter. The evolvement of different liver diseases - just like alcoholic and non-alcoholic fatty liver disease, steatohepatitis, cirrhosis or hepatocellular carcinoma - correlates with the changed composition and activity of gut microbiome. Thus, it can be hypothesized that pre-, pro- and antibiotics could have an impact on the treatment of these diseases. In our review article, the relationship between intestinal flora and liver diseases with different etiologies as well as therapeutic possibilities are discussed. Orv Hetil. 2018; 159(36): 1465-1474.
肠道中的微生物群落，即肠道微生物群与宿主共生，有助于宿主的内环境稳定，同时也对其产生影响。可以推测，肠道微生物群在肠道和肠外疾病的病理生理学中起着核心作用：决定疾病的发生、发展和并发症。最近，肠道微生物群已成为研究中一个备受关注的领域和重要课题，尤其是在肝病学领域。它是相关研究的焦点，因为肝脏作为一个过滤器，首先接触营养物质、细菌成分、毒素和代谢产物。不同肝病的发展——如酒精性和非酒精性脂肪性肝病、脂肪性肝炎、肝硬化或肝细胞癌——与肠道微生物群组成和活性的变化相关。因此，可以假设益生元、益生菌和抗生素可能对这些疾病的治疗产生影响。在我们的综述文章中，讨论了不同病因的肠道菌群与肝病之间的关系以及治疗可能性。《匈牙利医学周报》。2018年；159(36):1465 - 1474。
